{"FP": [{"generated": ["description"], "gold": [], "text": "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event."}, {"generated": ["surgical removal"], "gold": [], "text": "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection."}, {"generated": ["case report"], "gold": [], "text": "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use."}, {"generated": ["clinical pharmacist"], "gold": [], "text": "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1)."}, {"generated": ["patient's PGx results"], "gold": [], "text": "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected."}, {"generated": ["South Korean population"], "gold": [], "text": "In South Korean population reported a range from 29% to 83% [5]."}, {"generated": ["significantly associated"], "gold": [], "text": "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043)."}, {"generated": ["clinical effect of traditional hypoglycemic herbs"], "gold": [], "text": "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs."}, {"generated": ["this study"], "gold": [], "text": "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities."}, {"generated": ["extraction"], "gold": [], "text": "Extraction was performed using water to mimic the indigenous mode of extraction."}, {"generated": ["studies"], "gold": [], "text": "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7]."}, {"generated": ["Elliot et al."], "gold": [], "text": "Elliot et al."}, {"generated": ["polymerase chain reaction-RFLP analysis"], "gold": [], "text": "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis."}, {"generated": ["PCR"], "gold": [], "text": "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM)."}, {"generated": ["Tables 1, 2, 3", "Case 1"], "gold": [], "text": "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3."}, {"generated": ["Tables 1, 2, 3", "Case 1"], "gold": [], "text": "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3."}, {"generated": ["case"], "gold": [], "text": "This case culminated in liver failure despite discontinuation of the herbal supplement [4]."}, {"generated": ["study"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["Naranjo [8] Causality Scale"], "gold": [], "text": "Naranjo [8] Causality Scale for Adverse Drug Reactions."}, {"generated": ["findings"], "gold": [], "text": "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices."}, {"generated": ["analysis"], "gold": [], "text": "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%."}, {"generated": ["Ali and Khan, 2011"], "gold": [], "text": "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011)."}, {"generated": ["qualitative screening"], "gold": [], "text": "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4."}, {"generated": ["study with figure"], "gold": [], "text": "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c)."}, {"generated": ["study"], "gold": [], "text": "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel."}, {"generated": ["secondary objective", "safety parameters", "assess the effect of E. purpurea supplementation", "National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)", "grade 3 and 4 toxicities", "version 3.0", "docetaxel"], "gold": [], "text": "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)]."}, {"generated": ["secondary objective", "safety parameters", "assess the effect of E. purpurea supplementation", "National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)", "grade 3 and 4 toxicities", "version 3.0", "docetaxel"], "gold": [], "text": "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)]."}, {"generated": ["secondary objective", "safety parameters", "assess the effect of E. purpurea supplementation", "National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)", "grade 3 and 4 toxicities", "version 3.0", "docetaxel"], "gold": [], "text": "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)]."}, {"generated": ["secondary objective", "safety parameters", "assess the effect of E. purpurea supplementation", "National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)", "grade 3 and 4 toxicities", "version 3.0", "docetaxel"], "gold": [], "text": "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)]."}, {"generated": ["secondary objective", "safety parameters", "assess the effect of E. purpurea supplementation", "National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)", "grade 3 and 4 toxicities", "version 3.0", "docetaxel"], "gold": [], "text": "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)]."}, {"generated": ["secondary objective", "safety parameters", "assess the effect of E. purpurea supplementation", "National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)", "grade 3 and 4 toxicities", "version 3.0", "docetaxel"], "gold": [], "text": "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)]."}, {"generated": ["secondary objective", "safety parameters", "assess the effect of E. purpurea supplementation", "National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)", "grade 3 and 4 toxicities", "version 3.0", "docetaxel"], "gold": [], "text": "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)]."}, {"generated": ["pharmacokinetic parameters"], "gold": [], "text": "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax)."}, {"generated": ["Figure 3"], "gold": [], "text": "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3."}, {"generated": ["sixteen subjects"], "gold": [], "text": "Sixteen subjects reported 27 adverse events."}, {"generated": ["this study"], "gold": [], "text": "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study."}, {"generated": ["RGE repeated administration group", "control group"], "gold": [], "text": "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group."}, {"generated": ["RGE repeated administration group", "control group"], "gold": [], "text": "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group."}, {"generated": ["rats", "1 week", "2 weeks"], "gold": [], "text": "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored."}, {"generated": ["rats", "1 week", "2 weeks"], "gold": [], "text": "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored."}, {"generated": ["rats", "1 week", "2 weeks"], "gold": [], "text": "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored."}, {"generated": ["investigated", "rats"], "gold": [], "text": "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats."}, {"generated": ["investigated", "rats"], "gold": [], "text": "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats."}, {"generated": ["Table 2", "Table 1"], "gold": [], "text": "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2)."}, {"generated": ["Table 2", "Table 1"], "gold": [], "text": "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2)."}, {"generated": ["Bautista et al.", "2016"], "gold": [], "text": "2016; Bautista et\u00a0al."}, {"generated": ["Bautista et al.", "2016"], "gold": [], "text": "2016; Bautista et\u00a0al."}, {"generated": ["Dybro et al.", "2014"], "gold": [], "text": "2014; Dybro et\u00a0al."}, {"generated": ["Dybro et al.", "2014"], "gold": [], "text": "2014; Dybro et\u00a0al."}, {"generated": ["Rat liver microsomes"], "gold": [], "text": "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC."}, {"generated": ["present study"], "gold": [], "text": "In the present study, the selectivity was examined using independent plasma samples from six different rats."}, {"generated": ["data"], "gold": [], "text": "These data indicated that the accuracy and precision of the method were satisfactory."}, {"generated": ["experiments in mice"], "gold": [], "text": "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection."}, {"generated": ["extraction"], "gold": [], "text": "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2)."}, {"generated": ["determined using"], "gold": [], "text": "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH."}, {"generated": ["IC50 values", "concentration-response curves"], "gold": [], "text": "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq."}, {"generated": ["IC50 values", "concentration-response curves"], "gold": [], "text": "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq."}, {"generated": ["curve fitting"], "gold": [], "text": "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA)."}, {"generated": ["this study"], "gold": [], "text": "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans."}, {"generated": ["examine"], "gold": [], "text": "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes."}, {"generated": ["context of their DDI potential"], "gold": [], "text": "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential."}, {"generated": ["LC-MS/MS system", "Agilent 6470 Triple Quadrupole"], "gold": [], "text": "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA)."}, {"generated": ["LC-MS/MS system", "Agilent 6470 Triple Quadrupole"], "gold": [], "text": "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA)."}, {"generated": ["preparation of quality control (QC) samples"], "gold": [], "text": "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves."}, {"generated": ["post-preparative stability"], "gold": [], "text": "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples)."}, {"generated": ["rat"], "gold": [], "text": "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO."}, {"generated": ["product ion scan results"], "gold": [], "text": "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1)."}, {"generated": ["study"], "gold": [], "text": "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6."}, {"generated": ["University of Cape Town Human Research Ethics committee"], "gold": [], "text": "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014."}, {"generated": ["7 \u00b1 1-day", "each participant", "received three treatments", "washout period"], "gold": [], "text": "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between."}, {"generated": ["7 \u00b1 1-day", "each participant", "received three treatments", "washout period"], "gold": [], "text": "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between."}, {"generated": ["7 \u00b1 1-day", "each participant", "received three treatments", "washout period"], "gold": [], "text": "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between."}, {"generated": ["7 \u00b1 1-day", "each participant", "received three treatments", "washout period"], "gold": [], "text": "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between."}, {"generated": ["simulation scenarios"], "gold": [], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": ["study"], "gold": [], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": ["pharmacokinetic analysis", "non-compartmental analysis"], "gold": [], "text": "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP."}, {"generated": ["pharmacokinetic analysis", "non-compartmental analysis"], "gold": [], "text": "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP."}, {"generated": ["probe drug administration"], "gold": [], "text": "Adherence to these restrictions was further emphasized five days before each probe drug administration."}, {"generated": ["investigation"], "gold": [], "text": "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation."}, {"generated": ["earlier study"], "gold": [], "text": "This finding also corroborates the results of an earlier study in young individuals."}, {"generated": ["study"], "gold": [], "text": "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort."}, {"generated": ["study 42"], "gold": [], "text": "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements."}, {"generated": ["studies"], "gold": [], "text": "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy."}, {"generated": ["aforementioned reports"], "gold": ["reports"], "text": "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme."}, {"generated": ["plasma quinine", "validated HPLC method", "using", "blood samples", "(3-hydroxyquinine)", "analyzed"], "gold": [], "text": "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method."}, {"generated": ["plasma quinine", "validated HPLC method", "using", "blood samples", "(3-hydroxyquinine)", "analyzed"], "gold": [], "text": "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method."}, {"generated": ["plasma quinine", "validated HPLC method", "using", "blood samples", "(3-hydroxyquinine)", "analyzed"], "gold": [], "text": "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method."}, {"generated": ["plasma quinine", "validated HPLC method", "using", "blood samples", "(3-hydroxyquinine)", "analyzed"], "gold": [], "text": "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method."}, {"generated": ["plasma quinine", "validated HPLC method", "using", "blood samples", "(3-hydroxyquinine)", "analyzed"], "gold": [], "text": "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method."}, {"generated": ["plasma quinine", "validated HPLC method", "using", "blood samples", "(3-hydroxyquinine)", "analyzed"], "gold": [], "text": "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method."}, {"generated": ["received a single oral dose of 600 mg quinine sulphate tablets", "first phase", "each subject in the respective groups"], "gold": [], "text": "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England)."}, {"generated": ["received a single oral dose of 600 mg quinine sulphate tablets", "first phase", "each subject in the respective groups"], "gold": [], "text": "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England)."}, {"generated": ["received a single oral dose of 600 mg quinine sulphate tablets", "first phase", "each subject in the respective groups"], "gold": [], "text": "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England)."}, {"generated": ["study groups"], "gold": [], "text": "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola."}, {"generated": ["77 participants", "Stage 2"], "gold": [], "text": "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo."}, {"generated": ["77 participants", "Stage 2"], "gold": [], "text": "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo."}, {"generated": ["MOS-HIV"], "gold": [], "text": "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group."}, {"generated": ["serial electrocardiograms"], "gold": ["both arms"], "text": "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table)."}, {"generated": ["study"], "gold": [], "text": "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups."}, {"generated": ["study performed by Roozbeh et al."], "gold": [], "text": "[27] In the study performed by Roozbeh et al."}, {"generated": ["standard curve"], "gold": [], "text": "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time."}, {"generated": ["calculation"], "gold": [], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["two-compartment pharmacokinetic model", "indirect pharmacodynamic model", "percentage of prothrombin complex activity (PCA)", "INR data", "S-warfarin concentration\u2013time data", "pharmacokinetic model"], "gold": [], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "indirect pharmacodynamic model", "percentage of prothrombin complex activity (PCA)", "INR data", "S-warfarin concentration\u2013time data", "pharmacokinetic model"], "gold": [], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "indirect pharmacodynamic model", "percentage of prothrombin complex activity (PCA)", "INR data", "S-warfarin concentration\u2013time data", "pharmacokinetic model"], "gold": [], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "indirect pharmacodynamic model", "percentage of prothrombin complex activity (PCA)", "INR data", "S-warfarin concentration\u2013time data", "pharmacokinetic model"], "gold": [], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "indirect pharmacodynamic model", "percentage of prothrombin complex activity (PCA)", "INR data", "S-warfarin concentration\u2013time data", "pharmacokinetic model"], "gold": [], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "indirect pharmacodynamic model", "percentage of prothrombin complex activity (PCA)", "INR data", "S-warfarin concentration\u2013time data", "pharmacokinetic model"], "gold": [], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["(2007)", "investigated", "found"], "gold": [], "text": "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin."}, {"generated": ["(2007)", "investigated", "found"], "gold": [], "text": "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin."}, {"generated": ["(2007)", "investigated", "found"], "gold": [], "text": "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin."}, {"generated": ["(2007)"], "gold": [], "text": "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess."}, {"generated": ["they"], "gold": [], "text": "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4."}, {"generated": ["recommended"], "gold": [], "text": "It therefore was recommended that they should be avoided in the elderly [10, 12]."}, {"generated": ["search"], "gold": [], "text": "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany)."}, {"generated": ["participants"], "gold": [], "text": "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days."}, {"generated": ["study with duration", "12 weeks"], "gold": [], "text": "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51]."}, {"generated": ["study with duration", "12 weeks"], "gold": [], "text": "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51]."}, {"generated": ["assessing and minimizing clinical risks"], "gold": [], "text": "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks."}, {"generated": ["database for interactions of medicinal drugs (MedIQ)"], "gold": [], "text": "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data."}, {"generated": ["summary"], "gold": [], "text": "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence."}, {"generated": ["paper"], "gold": [], "text": "The authors declare that there is no conflict of interests regarding the publication of this paper."}, {"generated": ["post venlafaxine discontinuation"], "gold": [], "text": "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF."}, {"generated": ["case"], "gold": [], "text": "This was an important case of drug-induced cardiopulmonary toxicity."}, {"generated": ["present case"], "gold": [], "text": "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine."}, {"generated": ["this study"], "gold": [], "text": "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms."}, {"generated": ["consumption", "examination"], "gold": [], "text": "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups."}, {"generated": ["consumption", "examination"], "gold": [], "text": "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups."}, {"generated": ["clinical studies"], "gold": [], "text": "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group."}, {"generated": ["further research"], "gold": [], "text": "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects."}, {"generated": ["Dixon plots", "Lineweaver-Burk plots"], "gold": [], "text": "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive."}, {"generated": ["Dixon plots", "Lineweaver-Burk plots"], "gold": [], "text": "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive."}, {"generated": ["Figure 3C", "plot"], "gold": [], "text": "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM."}, {"generated": ["Figure 3C", "plot"], "gold": [], "text": "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM."}, {"generated": ["study"], "gold": [], "text": "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24]."}, {"generated": ["study by Du et al."], "gold": [], "text": "The previous study performed by Du et al."}, {"generated": ["inhibition kinetic analysis"], "gold": [], "text": "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation."}, {"generated": ["study"], "gold": [], "text": "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B)."}, {"generated": ["blood samples"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1-week repeated administration of red ginseng extract (RGE)"], "gold": [], "text": "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE)."}, {"generated": ["pharmacokinetic parameters"], "gold": [], "text": "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats."}, {"generated": ["24 subjects", "study participants"], "gold": [], "text": "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised."}, {"generated": ["24 subjects", "study participants"], "gold": [], "text": "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised."}, {"generated": ["study"], "gold": [], "text": "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13]."}, {"generated": ["study"], "gold": [], "text": "Furthermore, it decreases insulin and blood glucose markedly [17]."}, {"generated": ["study using 1,1\u2032,3,3\u2032-tetramethoxypropane"], "gold": [], "text": "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL)."}, {"generated": ["descriptive statistics"], "gold": [], "text": "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable."}, {"generated": ["group 3: CC with herbal mixture (n = 25)", "randomly allocated", "group 1: CC (n = 25)", "group 2: herbal mixture (n = 25)", "75 participants", "3 groups"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["group 3: CC with herbal mixture (n = 25)", "randomly allocated", "group 1: CC (n = 25)", "group 2: herbal mixture (n = 25)", "75 participants", "3 groups"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["group 3: CC with herbal mixture (n = 25)", "randomly allocated", "group 1: CC (n = 25)", "group 2: herbal mixture (n = 25)", "75 participants", "3 groups"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["group 3: CC with herbal mixture (n = 25)", "randomly allocated", "group 1: CC (n = 25)", "group 2: herbal mixture (n = 25)", "75 participants", "3 groups"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["group 3: CC with herbal mixture (n = 25)", "randomly allocated", "group 1: CC (n = 25)", "group 2: herbal mixture (n = 25)", "75 participants", "3 groups"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["group 3: CC with herbal mixture (n = 25)", "randomly allocated", "group 1: CC (n = 25)", "group 2: herbal mixture (n = 25)", "75 participants", "3 groups"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["Polycystic ovary syndrome (PCOS)", "Patients' flow diagram"], "gold": [], "text": "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram."}, {"generated": ["Polycystic ovary syndrome (PCOS)", "Patients' flow diagram"], "gold": [], "text": "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram."}, {"generated": ["safety was evaluated"], "gold": [], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": ["pharmacokinetics"], "gold": [], "text": "Darunavir pharmacokinetics."}, {"generated": ["study", "coadministration of E. purpurea"], "gold": [], "text": "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively."}, {"generated": ["study", "coadministration of E. purpurea"], "gold": [], "text": "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively."}, {"generated": ["Figure", "Table"], "gold": [], "text": "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea."}, {"generated": ["Figure", "Table"], "gold": [], "text": "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea."}, {"generated": ["in vivo activity", "humans"], "gold": [], "text": "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions."}, {"generated": ["in vivo activity", "humans"], "gold": [], "text": "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions."}, {"generated": ["8 days"], "gold": [], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["evaluation of phenotyping metrics"], "gold": [], "text": "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins."}, {"generated": ["study selection and data extraction"], "gold": [], "text": "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers."}, {"generated": ["consent form", "subject enrollment", "study protocol"], "gold": [], "text": "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment."}, {"generated": ["consent form", "subject enrollment", "study protocol"], "gold": [], "text": "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment."}, {"generated": ["consent form", "subject enrollment", "study protocol"], "gold": [], "text": "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment."}, {"generated": ["his/her Siliphos", "each subject", "received"], "gold": [], "text": "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable."}, {"generated": ["his/her Siliphos", "each subject", "received"], "gold": [], "text": "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable."}, {"generated": ["his/her Siliphos", "each subject", "received"], "gold": [], "text": "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable."}, {"generated": ["drug development"], "gold": [], "text": "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development."}, {"generated": ["study"], "gold": [], "text": "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3)."}, {"generated": ["literature search"], "gold": [], "text": "In order to achieve a comprehensive literature search, a total of eleven databases were searched."}, {"generated": ["identifying", "highlighted"], "gold": [], "text": "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines."}, {"generated": ["identifying", "highlighted"], "gold": [], "text": "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines."}, {"generated": ["interviewed patients"], "gold": [], "text": "A summary of the background characteristics of the interviewed patients is given in Table 1."}, {"generated": ["pharmacological management", "tabular summary"], "gold": [], "text": "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents."}, {"generated": ["pharmacological management", "tabular summary"], "gold": [], "text": "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents."}, {"generated": ["clinical combined application"], "gold": [], "text": "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs."}, {"generated": ["UPLC-MS/MS analysis", "LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)", "UPLC system (Thermo Fisher Scientific, Waltham, MA, USA)"], "gold": [], "text": "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)."}, {"generated": ["UPLC-MS/MS analysis", "LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)", "UPLC system (Thermo Fisher Scientific, Waltham, MA, USA)"], "gold": [], "text": "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)."}, {"generated": ["UPLC-MS/MS analysis", "LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)", "UPLC system (Thermo Fisher Scientific, Waltham, MA, USA)"], "gold": [], "text": "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)."}, {"generated": ["method of Furlong et al"], "gold": [], "text": "The influence test for PON was conducted by the method of Furlong et al."}, {"generated": ["present work"], "gold": [], "text": "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS."}, {"generated": ["testing"], "gold": [], "text": "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B)."}, {"generated": ["described previously", "flow cytometry"], "gold": [], "text": "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24]."}, {"generated": ["described previously", "flow cytometry"], "gold": [], "text": "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24]."}, {"generated": ["previously"], "gold": [], "text": "Data were evaluated as described previously [28]."}, {"generated": ["concentration-dependent effect"], "gold": [], "text": "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity."}, {"generated": ["effects of rifampicin (20 \u00b5M)", "effects of Samento (0.033\u20131%)"], "gold": [], "text": "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure."}, {"generated": ["effects of rifampicin (20 \u00b5M)", "effects of Samento (0.033\u20131%)"], "gold": [], "text": "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure."}, {"generated": ["effect of Samento on CYP2J2 mRNA decay in LS180 cells"], "gold": [], "text": "Effect of Samento on CYP2J2 mRNA decay in LS180 cells."}, {"generated": ["RT-PCR"], "gold": [], "text": "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0."}, {"generated": ["subjects", "study period"], "gold": [], "text": "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period."}, {"generated": ["subjects", "study period"], "gold": [], "text": "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period."}, {"generated": ["CYP2B6 genotyping"], "gold": [], "text": "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13]."}, {"generated": ["analytical data", "version 1.4", "processed using", "Foster City, CA", "Analyst software", "Applied Biosystems"], "gold": [], "text": "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA)."}, {"generated": ["analytical data", "version 1.4", "processed using", "Foster City, CA", "Analyst software", "Applied Biosystems"], "gold": [], "text": "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA)."}, {"generated": ["analytical data", "version 1.4", "processed using", "Foster City, CA", "Analyst software", "Applied Biosystems"], "gold": [], "text": "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA)."}, {"generated": ["analytical data", "version 1.4", "processed using", "Foster City, CA", "Analyst software", "Applied Biosystems"], "gold": [], "text": "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA)."}, {"generated": ["analytical data", "version 1.4", "processed using", "Foster City, CA", "Analyst software", "Applied Biosystems"], "gold": [], "text": "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA)."}, {"generated": ["analytical data", "version 1.4", "processed using", "Foster City, CA", "Analyst software", "Applied Biosystems"], "gold": [], "text": "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA)."}, {"generated": ["within-subject data"], "gold": [], "text": "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data."}, {"generated": ["this study"], "gold": [], "text": "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion."}, {"generated": ["study with rats"], "gold": [], "text": "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05)."}, {"generated": ["study"], "gold": [], "text": "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B."}, {"generated": ["APG-pretreated rats", "rats", "BCPR/ABCG2 protein"], "gold": [], "text": "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05)."}, {"generated": ["APG-pretreated rats", "rats", "BCPR/ABCG2 protein"], "gold": [], "text": "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05)."}, {"generated": ["APG-pretreated rats", "rats", "BCPR/ABCG2 protein"], "gold": [], "text": "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05)."}, {"generated": ["current study"], "gold": [], "text": "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact."}, {"generated": ["Group I", "Group II"], "gold": [], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": ["Group I", "Group II"], "gold": [], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": ["Group IV", "7th day", "APG 40 mg/kg", "APG administration"], "gold": [], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["Group IV", "7th day", "APG 40 mg/kg", "APG administration"], "gold": [], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["Group IV", "7th day", "APG 40 mg/kg", "APG administration"], "gold": [], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["Group IV", "7th day", "APG 40 mg/kg", "APG administration"], "gold": [], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["research"], "gold": [], "text": "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58)."}, {"generated": ["results"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["BCRP/ABCG2 protein expression", "DAS administration", "APG pretreatment", "intestinal (B)", "hepatic (A)", "rats"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["BCRP/ABCG2 protein expression", "DAS administration", "APG pretreatment", "intestinal (B)", "hepatic (A)", "rats"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["BCRP/ABCG2 protein expression", "DAS administration", "APG pretreatment", "intestinal (B)", "hepatic (A)", "rats"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["BCRP/ABCG2 protein expression", "DAS administration", "APG pretreatment", "intestinal (B)", "hepatic (A)", "rats"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["BCRP/ABCG2 protein expression", "DAS administration", "APG pretreatment", "intestinal (B)", "hepatic (A)", "rats"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["BCRP/ABCG2 protein expression", "DAS administration", "APG pretreatment", "intestinal (B)", "hepatic (A)", "rats"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["cytochrome P-450 (CYP) activity", "phytochemical-mediated modulation"], "gold": [], "text": "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions."}, {"generated": ["cytochrome P-450 (CYP) activity", "phytochemical-mediated modulation"], "gold": [], "text": "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions."}, {"generated": ["evaluate the effect of SC extract supplementation", "study"], "gold": [], "text": "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women."}, {"generated": ["evaluate the effect of SC extract supplementation", "study"], "gold": [], "text": "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women."}, {"generated": ["ANOVA results"], "gold": [], "text": "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions."}, {"generated": ["main test session"], "gold": [], "text": "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27]."}, {"generated": ["study"], "gold": [], "text": "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group."}, {"generated": ["groups"], "gold": [], "text": "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1)."}, {"generated": ["study"], "gold": [], "text": "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2."}, {"generated": ["database searching", "literature selection"], "gold": [], "text": "Figure\u00a01 summarizes the process of database searching and literature selection."}, {"generated": ["database searching", "literature selection"], "gold": [], "text": "Figure\u00a01 summarizes the process of database searching and literature selection."}, {"generated": ["within-run accuracy and precision of captopril analysis"], "gold": [], "text": "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3)."}, {"generated": ["selectivity testing"], "gold": [], "text": "In selectivity testing, six rats plasma was used."}, {"generated": ["experiment"], "gold": [], "text": "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups."}, {"generated": ["two weeks"], "gold": [], "text": "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter."}, {"generated": ["analysis"], "gold": [], "text": "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA)."}, {"generated": ["study"], "gold": [], "text": "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered."}, {"generated": ["present work"], "gold": [], "text": "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment."}, {"generated": ["our results"], "gold": [], "text": "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin."}, {"generated": ["experiments"], "gold": [], "text": "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group."}, {"generated": ["indomethacin-induced gastric injury"], "gold": [], "text": "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert."}, {"generated": ["study"], "gold": [], "text": "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig."}, {"generated": ["case report"], "gold": [], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": ["study number 7"], "gold": [], "text": "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy."}, {"generated": ["China"], "gold": [], "text": "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement."}, {"generated": ["three patients"], "gold": [], "text": "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin."}, {"generated": ["Randomized Controlled Trials (RCTs)"], "gold": ["RCT"], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": ["15 day study"], "gold": [], "text": "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18]."}, {"generated": ["clinically-relevant dose"], "gold": [], "text": "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure."}, {"generated": ["models"], "gold": [], "text": "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered."}, {"generated": ["inter-correlation"], "gold": [], "text": "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients)."}, {"generated": ["pharmacokinetic parameters", "prediction differences"], "gold": [], "text": "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated."}, {"generated": ["pharmacokinetic parameters", "prediction differences"], "gold": [], "text": "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated."}, {"generated": ["current study"], "gold": [], "text": "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates."}, {"generated": ["Gegen (240 or 480 mg/kg)", "Danshen (240 or 480 mg/kg)", "warfarin (0.2 mg/kg)", "both in isolation and combination", "sixty Sprague\u2013Dawley rats", "investigated the effects of"], "gold": [], "text": "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination."}, {"generated": ["Gegen (240 or 480 mg/kg)", "Danshen (240 or 480 mg/kg)", "warfarin (0.2 mg/kg)", "both in isolation and combination", "sixty Sprague\u2013Dawley rats", "investigated the effects of"], "gold": [], "text": "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination."}, {"generated": ["Gegen (240 or 480 mg/kg)", "Danshen (240 or 480 mg/kg)", "warfarin (0.2 mg/kg)", "both in isolation and combination", "sixty Sprague\u2013Dawley rats", "investigated the effects of"], "gold": [], "text": "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination."}, {"generated": ["Gegen (240 or 480 mg/kg)", "Danshen (240 or 480 mg/kg)", "warfarin (0.2 mg/kg)", "both in isolation and combination", "sixty Sprague\u2013Dawley rats", "investigated the effects of"], "gold": [], "text": "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination."}, {"generated": ["Gegen (240 or 480 mg/kg)", "Danshen (240 or 480 mg/kg)", "warfarin (0.2 mg/kg)", "both in isolation and combination", "sixty Sprague\u2013Dawley rats", "investigated the effects of"], "gold": [], "text": "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination."}, {"generated": ["Gegen (240 or 480 mg/kg)", "Danshen (240 or 480 mg/kg)", "warfarin (0.2 mg/kg)", "both in isolation and combination", "sixty Sprague\u2013Dawley rats", "investigated the effects of"], "gold": [], "text": "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination."}, {"generated": ["microsomes incubation", "Western blot", "Real Time-Polymerase Chain Reaction"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["microsomes incubation", "Western blot", "Real Time-Polymerase Chain Reaction"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["microsomes incubation", "Western blot", "Real Time-Polymerase Chain Reaction"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["analyzed", "monitored"], "gold": [], "text": "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis)."}, {"generated": ["analyzed", "monitored"], "gold": [], "text": "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis)."}, {"generated": ["positive control group"], "gold": [], "text": "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group."}, {"generated": ["no inductive effects were observed"], "gold": [], "text": "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group."}, {"generated": ["current study"], "gold": [], "text": "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG."}, {"generated": ["publication by Beer et al."], "gold": [], "text": "Sample preparation was based on the publication by (Beer et al."}, {"generated": ["human plasma"], "gold": [], "text": "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte."}, {"generated": ["80%", "48 women", "37 months", "4-113", "range", "mean"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["80%", "48 women", "37 months", "4-113", "range", "mean"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["80%", "48 women", "37 months", "4-113", "range", "mean"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["80%", "48 women", "37 months", "4-113", "range", "mean"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["80%", "48 women", "37 months", "4-113", "range", "mean"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["80%", "48 women", "37 months", "4-113", "range", "mean"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["this study"], "gold": [], "text": "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used."}, {"generated": ["aqueous extract of Moringa oleifera leaves"], "gold": [], "text": "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9."}, {"generated": ["(2000)"], "gold": [], "text": "(2000)."}, {"generated": ["female volunteers"], "gold": [], "text": "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation."}, {"generated": ["double-blinded treatments"], "gold": [], "text": "Double-blinded treatments were allocated using sequentially numbered drug containers."}, {"generated": ["Figure 4"], "gold": [], "text": "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04."}, {"generated": ["single oral dose"], "gold": [], "text": "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin."}, {"generated": ["investigated"], "gold": [], "text": "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin."}, {"generated": ["PCR-RFLP analysis"], "gold": [], "text": "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis."}, {"generated": ["study with table"], "gold": [], "text": "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate."}, {"generated": ["Gorski et al."], "gold": [], "text": "Gorski et al."}, {"generated": ["LC-MS"], "gold": [], "text": "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above."}, {"generated": ["patient"], "gold": [], "text": "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis."}, {"generated": ["rats"], "gold": [], "text": "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity."}, {"generated": ["studied herb/herbal components"], "gold": [], "text": "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components."}, {"generated": ["rat plasma"], "gold": [], "text": "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different."}, {"generated": ["European countries"], "gold": [], "text": "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries."}, {"generated": ["Rahate and Rajasekaran, 2015"], "gold": [], "text": "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015)."}, {"generated": ["pharmacokinetic- and tissue distribution-based HDIs studies"], "gold": [], "text": "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies."}, {"generated": ["Vance-Bryan et al., 1990"], "gold": [], "text": "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990)."}, {"generated": ["co-administration of CIP and PCE", "Figures 3, 4"], "gold": [], "text": "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively."}, {"generated": ["co-administration of CIP and PCE", "Figures 3, 4"], "gold": [], "text": "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively."}, {"generated": ["study"], "gold": [], "text": "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3)."}, {"generated": ["further research"], "gold": [], "text": "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion."}, {"generated": ["rats", "anesthesia with isoflurane"], "gold": [], "text": "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane."}, {"generated": ["rats", "anesthesia with isoflurane"], "gold": [], "text": "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane."}, {"generated": ["LC-MS/MS system control and data processing"], "gold": [], "text": "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing."}, {"generated": ["toxicological autopsy"], "gold": [], "text": "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs."}, {"generated": ["chronic use"], "gold": [], "text": "Chronic use of ginseng on its own has been associated with manic psychosis [90]."}, {"generated": ["21 healthy subjects", "2-way, open-label crossover study"], "gold": ["open-label crossover study"], "text": "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate."}, {"generated": ["21 healthy subjects", "2-way, open-label crossover study"], "gold": ["open-label crossover study"], "text": "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate."}, {"generated": ["case report"], "gold": [], "text": "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors."}, {"generated": ["this patient"], "gold": [], "text": "In this patient, we reported the possible effect of parsley juice on the level of sirolimus."}, {"generated": ["authorship", "research", "publication"], "gold": [], "text": "Funding: The authors received no financial support for the research, authorship, and/or publication of this article."}, {"generated": ["authorship", "research", "publication"], "gold": [], "text": "Funding: The authors received no financial support for the research, authorship, and/or publication of this article."}, {"generated": ["authorship", "research", "publication"], "gold": [], "text": "Funding: The authors received no financial support for the research, authorship, and/or publication of this article."}, {"generated": ["AUC data"], "gold": [], "text": "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil."}, {"generated": ["pretreatment period"], "gold": [], "text": "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect."}, {"generated": ["Spanish study"], "gold": [], "text": "A Spanish study reports Aloe vera [37]."}, {"generated": ["case report"], "gold": [], "text": "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117]."}, {"generated": ["refined quantified dry extract"], "gold": [], "text": "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154]."}, {"generated": ["applied atorvastatin in rats"], "gold": [], "text": "applied atorvastatin in rats after 3 weeks of drinking green tea or water."}, {"generated": ["humans"], "gold": [], "text": "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234]."}, {"generated": ["MTX doses between 7.5 and 15 mg weekly"], "gold": [], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": ["clinical significance"], "gold": [], "text": "The clinical significance of this phenomenon depends on individual susceptibility."}, {"generated": ["Schadel et al., 1995", "Barnhart, 1980"], "gold": [], "text": "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995)."}, {"generated": ["Schadel et al., 1995", "Barnhart, 1980"], "gold": [], "text": "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995)."}, {"generated": ["this study"], "gold": [], "text": "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study."}], "FN": [{"generated": [], "gold": ["pharmacogenomics studies", "clinic study"], "text": "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs."}, {"generated": [], "gold": ["pharmacogenomics studies", "clinic study"], "text": "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs."}, {"generated": [], "gold": ["DDI studies"], "text": "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI."}, {"generated": [], "gold": ["In vivo distribution studies"], "text": "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22]."}, {"generated": [], "gold": ["in vitro study"], "text": "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs."}, {"generated": [], "gold": ["clinical studies"], "text": "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome."}, {"generated": [], "gold": ["phase II clinical trials", "preclinical studies"], "text": "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline."}, {"generated": [], "gold": ["phase II clinical trials", "preclinical studies"], "text": "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline."}, {"generated": [], "gold": ["clinical studies"], "text": "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract."}, {"generated": [], "gold": ["surveys"], "text": "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age."}, {"generated": ["aforementioned reports"], "gold": ["reports"], "text": "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme."}, {"generated": ["serial electrocardiograms"], "gold": ["both arms"], "text": "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table)."}, {"generated": [], "gold": ["clinical trial", "clinical trials"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["clinical trial", "clinical trials"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["inhibition kinetic study"], "text": "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation."}, {"generated": [], "gold": ["randomized controlled trials"], "text": "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin."}, {"generated": [], "gold": ["randomized controlled trials (RCTs)"], "text": "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin."}, {"generated": [], "gold": ["trials"], "text": "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal."}, {"generated": [], "gold": ["case reports"], "text": "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship."}, {"generated": [], "gold": ["case reports"], "text": "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40]."}, {"generated": [], "gold": ["in vivo study"], "text": "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47]."}, {"generated": [], "gold": ["in vivo study"], "text": "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48]."}, {"generated": [], "gold": ["a randomized double-blinded control trial"], "text": "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder."}, {"generated": [], "gold": ["in vitro"], "text": "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters."}, {"generated": [], "gold": ["in vitro"], "text": "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions."}, {"generated": [], "gold": ["in vivo studies"], "text": "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings."}, {"generated": [], "gold": ["reports"], "text": "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago."}, {"generated": [], "gold": ["in vitro", "in vivo"], "text": "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression."}, {"generated": [], "gold": ["in vitro", "in vivo"], "text": "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression."}, {"generated": [], "gold": ["preclinical studies"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": [], "gold": ["Clinical studies"], "text": "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313]."}, {"generated": [], "gold": ["pharmacodynamic study"], "text": "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study."}, {"generated": [], "gold": ["Animal studies"], "text": "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner."}, {"generated": ["Randomized Controlled Trials (RCTs)"], "gold": ["RCT"], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": [], "gold": ["RCT"], "text": "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems."}, {"generated": [], "gold": ["In vitro and in vivo studies"], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": [], "gold": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"], "text": "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions."}, {"generated": [], "gold": ["in vitro study"], "text": "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability."}, {"generated": [], "gold": ["trial designs"], "text": "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3."}, {"generated": [], "gold": ["case reports", "clinical reports"], "text": "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322]."}, {"generated": [], "gold": ["case reports", "clinical reports"], "text": "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322]."}, {"generated": [], "gold": ["in vitro and in vivo"], "text": "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58]."}, {"generated": [], "gold": ["in vivo effects"], "text": "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB."}, {"generated": [], "gold": ["in vitro", "in vivo"], "text": "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results."}, {"generated": [], "gold": ["in vitro", "in vivo"], "text": "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results."}, {"generated": [], "gold": ["In vitro"], "text": "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008)."}, {"generated": [], "gold": ["in vivo herb\u2013drug interaction studies", "In vitro herb\u2013drug interactions studies"], "text": "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013)."}, {"generated": [], "gold": ["in vivo herb\u2013drug interaction studies", "In vitro herb\u2013drug interactions studies"], "text": "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013)."}, {"generated": [], "gold": ["in vitro"], "text": "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb."}, {"generated": [], "gold": ["Case Report", "case report"], "text": "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes."}, {"generated": [], "gold": ["Case Report", "case report"], "text": "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes."}, {"generated": [], "gold": ["Clinical studies"], "text": "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9]."}, {"generated": [], "gold": ["In vitro CYP assays"], "text": "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions."}, {"generated": [], "gold": ["in-vitro experiments"], "text": "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism."}, {"generated": [], "gold": ["in-vitro screening", "ex-vivo", "in-vivo"], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": [], "gold": ["in-vitro screening", "ex-vivo", "in-vivo"], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": [], "gold": ["in-vitro screening", "ex-vivo", "in-vivo"], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": [], "gold": ["pre-clinical studies"], "text": "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking."}, {"generated": [], "gold": ["Several controlled clinical studies"], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": [], "gold": ["human studies"], "text": "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88]."}, {"generated": ["21 healthy subjects", "2-way, open-label crossover study"], "gold": ["open-label crossover study"], "text": "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate."}, {"generated": [], "gold": ["in vitro experiments"], "text": "There are in vitro experiments confirming thrombin inhibition [172]."}, {"generated": [], "gold": ["vivo in several studies"], "text": "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996)."}, {"generated": [], "gold": ["in vitro study"], "text": "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig."}, {"generated": [], "gold": ["vivo study"], "text": "The in vivo study was conducted on healthy human volunteers."}, {"generated": [], "gold": ["clinical study"], "text": "Therefore, the clinical study was conducted to confirm the in vitro results."}]}